Finance

Beta
Lists
NGNE:NASDAQ
Neurogene Inc
$31.45
-2.57%
(-0.83) 1D
$31.47
+0.06% (+0.020)
After hours
Closed: Jun 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NGNE...
Open
$32.28
High
$32.96
Low
$30.34
Mkt. cap
496.97M
Avg. vol.
177.68K
Volume
162.36K
52-wk high
$37.27
52-wk low
$14.65
EPS
-$4.54
Beta
1.69
Shares outstanding
15.80M
No. of employees
131
Open
$32.28
High
$32.96
Low
$30.34
Mkt. cap
496.97M
Avg. vol.
177.68K
Volume
162.36K
52-wk high
$37.27
52-wk low
$14.65
EPS
-$4.54
Beta
1.69
Shares outstanding
15.80M
No. of employees
131
News stories
From sources across the web
About Neurogene Inc
CEOJonathan Drachman M.D.
Employees131
Founded2018
Headquarters-
SectorBiotechnology
Websiteneurogene.com
Analyst ratings
Based on 9 analysts giving stock ratings to NGNE in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for NGNE in the last 3 months.
Highest
Current $31.45
$180.00 (+472.34%)
Average
$80.00 (+154.37%)
Lowest
$46.00 (+46.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$69.00
+119.4%
06/30/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$180.00
+472.3%
06/29/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$70.00
+122.6%
06/30/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
06/29/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$60.00
+90.8%
06/29/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$70.00
+122.6%
06/03/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$65.00
+106.7%
05/15/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
05/13/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$46.00
+46.3%
05/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
19.37M
17.24M
20.52M
25.15M
Cost of revenue
19.37M
17.24M
20.52M
25.15M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.72M
6.56M
6.89M
8.20M
Operating expense
6.72M
6.56M
6.89M
8.20M
Total operating expenses
26.08M
23.80M
27.41M
33.35M
Operating income
-26.08M
-23.80M
-27.41M
-33.35M
Other non operating income
1.14M
107.00K
122.00K
154.00K
EBT including unusual items
-22.02M
-20.95M
-24.74M
-30.93M
EBT excluding unusual items
-22.02M
-20.95M
-24.62M
-30.93M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-22.02M
-20.95M
-24.74M
-30.93M
Net profit margin
-
-
-
-
Earnings per share
-1.05
-0.99
-1.13
-1.39
Interest and investment income
2.93M
2.74M
2.67M
2.26M
Interest expense
-1.00K
-1.00K
-1.00K
-
Net interest expenses
2.93M
2.74M
2.67M
2.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.31M
-23.02M
-26.62M
-32.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer